22 results on '"Stinchcombe, T."'
Search Results
2. Immunohistochemical-based diagnosis of lung adenocarcinoma subtypes reproduces the results of gene expression profiling.
3. Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC.
4. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors.
5. Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).
6. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
7. Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts)
8. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
9. Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801
10. A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)
11. Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
12. A phase I trial of pemetrexed and vinflunine (VFL)
13. Molecular markers distinguish patients at differential risk of brain metastases in lung cancer by immunohistochemistry
14. Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
15. Inter-observer reliability for the diagnosis of lung cancer in a clinical cohort using the WHO classification system, version
16. Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer
17. Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies
18. Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: Association with atopic phenotype
19. Feasibility of adjuvant carboplatin/docetaxel (C/D) in patients (pts) resected stage I-IIIB non-small cell lung cancer (NSCLC): Preliminary report of a phase II trial
20. Predictive model for mediastinal lymph node status at the time of mediastinoscopy
21. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC)
22. Induction chemotherapy using carboplatin (C), irinotecan (I), and paclitaxel (P) with pegfilgrastim support followed by concurrent thoracic conformal radiation therapy (TCRT) with weekly CP and daily gefitinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.